JY-302 by Jin Yang Pharmaceutical for Type 2 Diabetes: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
JY-302 overview
JY-302 is under development for the treatment of type 2 diabetes. The therapeutic candidate is an incrementally modified drug and acts by targeting sodium-glucose co-transporter 2 (SGLT2). It is administered through oral route.
For a complete picture of JY-302’s drug-specific PTSR and LoA scores, buy the report here.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#JY302 #Jin #Yang #Pharmaceutical #Type #Diabetes #Likelihood #Approval
